Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $39.1 million.

  • Zentalis Pharmaceuticals' Cash & Equivalents fell 544.05% to $39.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.1 million, marking a year-over-year decrease of 544.05%. This contributed to the annual value of $33.9 million for FY2024, which is 2091.09% up from last year.
  • As of Q3 2025, Zentalis Pharmaceuticals' Cash & Equivalents stood at $39.1 million, which was down 544.05% from $37.6 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' Cash & Equivalents' 5-year high stood at $266.6 million during Q2 2023, with a 5-year trough of $28.0 million in Q4 2023.
  • Over the past 4 years, Zentalis Pharmaceuticals' median Cash & Equivalents value was $39.1 million (recorded in 2025), while the average stood at $58.8 million.
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Cash & Equivalents skyrocketed by 38339.41% in 2023, and later tumbled by 8612.83% in 2024.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Cash & Equivalents stood at $43.1 million in 2022, then crashed by 34.9% to $28.0 million in 2023, then rose by 20.91% to $33.9 million in 2024, then grew by 15.25% to $39.1 million in 2025.
  • Its Cash & Equivalents stands at $39.1 million for Q3 2025, versus $37.6 million for Q2 2025 and $41.9 million for Q1 2025.